Latest

Diagnostic Challenges in the Era of Genetically Targeting Master Brands

Companies developing potential master brands need to begin work much earlier in the clinical development program to ensure reliable diagnostics will be available to all potential patients, writes Barri Blauvelt.

Reinventing the Role of Medical Affairs

As digital technologies transform drug development and marketing, a retooled medical affairs function can be a competitive differentiator, write Loic Plantevin, Christoph Schlegel and Maria Gordian.

Pharm Exec's Emerging Pharma Leaders 2017 — Call for Nominations

Read more for details of how to nominate a colleague — or yourself — for Pharm Exec's Emerging Pharma Leaders 2017

2017 Brands of the Year: 5 Impact Areas

In its 11th annual feature, Pharm Exec breaks from the norm to instead profile five products that are currently shining the spotlight on critical and highly debated aspects of healthcare and R&D.

PharmExec Videos

New & Noteworthy

FDA Looks to Advance Regenerative Medicine

CBER is gearing up to facilitate the development and approval of regenerative medicine advanced therapies, as defined by the 21st Century Cures Act.

IDMP: A Big Data Challenge for European Pharma

Pharm Exec speaks to Andrew Marr about the implications of the European Union's new IDMP (Identification of Medicinal Products) regulations for the pharma industry.

Understanding the Digital Workplace

The digital workplace is defined as a “business strategy to boost employee engagement and agility through a more consumerized work environment”. But what does this mean for life sciences organizations? Michael Woodbridge explains.

Fast-Performing Leadership

Pharma and biotech needs to cultivate fast-performing leadership. Bagrat Lalayan outlines a model to get the best results in a competitive business environment.

Brand of the Year: A Retrospective

With this year marking our 11th installment, we look back on Pharm Exec's first 10 Brands of the Year.

Sales & Marketing

Reinventing the Role of Medical Affairs

As digital technologies transform drug development and marketing, a retooled medical affairs function can be a competitive differentiator, write Loic Plantevin, Christoph Schlegel and Maria Gordian.

Pharma Must Embrace Its Social Media Role

The absence of pharma brands on social media creates a significant void of reputable healthcare information to aid patients, writes Dawn Lacallade.

Merck’s Latest Shot Against Shingles

New DTC campaign for its vaccine Zostavax uses a more serious, personal messaging approach—as pharmas look to close the conversation gaps between patients and healthcare providers.

Featured E-Books

 

Securing the Global Supply Chain: Strategies for Operational Excellence

Strategic management of the supply chain is vital to winning with customers. Cost and quality are important, but they are not the only things customers care about: New services, flexibility in  relationships, supply reliability, and creatively overcoming obstacles in delivery of products are also core values. Pharmaceutical product portfolios and customers are becoming more complex. To stay ahead, customer-focused supply-chain capabilities is becoming an increasingly crucial part of a company’s competitive advantage. Download the eBook.

 

The Changing Contours of Drug Commercialization

"The Changing Contours of Drug Commercialization," a new e-book from the editors of Pharmaceutical Executive, sheds light on solutions and strategies uniquely within a manufacturer's own sphere of control that can help navigate the often unforgiving transition from registration to the real-world battle for clinical acceptance and market share. Download the eBook.

 

Patient-Centric Approach to Product Commercialization

The industry's much talked-about patient-centered approach requires more than lip-service and organizational redesigns. In order for the patient to emerge center stage in a commercial approach, it's necessary for manufacturers to shift prioritization's to help the greatest number of patients gain access and remain on treatments.

 

The Path To Market Access: Winning Strategies To Build Value With Payers

Success in today’s rapidly changing market access world depends on understanding your product’s value through the eyes of payers and shaping crucial value communication around the needs of market access stakeholders as much as it does on developing solid evidence of the value of your product.

 

 

View all e-books

PEspeaks

Future Pharma Leaders will be Failures

Experts say knowing how to lead in uncertain times and being open to change is just as important as a degree.

Amazon and Pharma: Is the Hype Real?

Analysts who spoke with Pharm Exec expect the online retail giant to enter the pharma space within the next two years.

Europe: A Long Hot Summer of Drug Pricing Tension

In the hothouse atmosphere of European governments' anxieties over ever more expensive medicines, recent weeks have seen perspiration breaking out on the brows of ministers, officials and drug company executives, writes Reflector.

UK Political Parties Set Out Pharma Stalls Ahead of June Election

With the UK's General Election set for June 8, Leela Barham looks what the competing parties are promising for pharma and healthcare

FDA Gets Closer to Creating Digital Health Unit

There will be 13 full-time positions dedicated to creating and providing guidance in the emerging subject area.

New Directions in Marketing

For the pharma industry, keeping up with new technology platforms and promotional techniques is vital when it comes to optimizing its marketing efforts.
 

These articles from Pharmaceutical Executive help will help marketers stay on message and, crucially, up to date in a field that is changing faster than ever.
 

Read More.

Interviews

IDMP: A Big Data Challenge for European Pharma

Pharm Exec speaks to Andrew Marr about the implications of the European Union's new IDMP (Identification of Medicinal Products) regulations for the pharma industry.

Understanding the Digital Workplace

The digital workplace is defined as a “business strategy to boost employee engagement and agility through a more consumerized work environment”. But what does this mean for life sciences organizations? Michael Woodbridge explains.

Merck’s Latest Shot Against Shingles

New DTC campaign for its vaccine Zostavax uses a more serious, personal messaging approach—as pharmas look to close the conversation gaps between patients and healthcare providers.

HBA's Woman of the Year 2017

Pharm Exec profiles Bahija Jallal, this year's Healthcare Businesswomen’s Association Woman of the Year.

Advancing Rare Disease R&D: A Mission Update

Six years in, Pharm Exec looks at the progress of the International Rare Diseases Research Consortium.

A Vision for Vaccines

Pharm Exec talks to Hugo Fry, Sanofi’s General Manager for the UK and General Manager for Sanofi Pasteur UK and Ireland, about his vision for the company and the vaccine space in these markets.

Regulatory

FDA Looks to Advance Regenerative Medicine

CBER is gearing up to facilitate the development and approval of regenerative medicine advanced therapies, as defined by the 21st Century Cures Act.

Gottlieb Faces Multiple Challenges at FDA

Now that the Senate has confirmed Scott Gottlieb as FDA commissioner, Jill Wechsler outlines a few of the issues awaiting the agency's new leader.

FDA Moves Forward on Mutual GMP Inspections with Europe

The agency hopes to better use global resources and avoid duplicate inspections of foreign facilities.

Tackling the Prior Authorization Challenge: A Critical Task for Pharma

Effectively addressing prior authorization challenges as part of a company’s core sales and marketing tactics can yield tangible and substantial benefits, writes Dan Rubin.

From the Editor

Don’t be the Next #Hashtag

Recent PR disasters in other industries raise an important reputational question that can apply to pharma as well: do you want to be someone that works the system or improves the system?

When Rare Becomes Common

Two topics in Pharm Exec this month—rare disease research and women in healthcare leadership—share a "common" thread.

Big Money and Big Data

No longer just hype, investing in big data is the path to the future for pharma, even if big returns aren't a direct result, writes Pharm Exec Editor Lisa Henderson.

lorem ipsum